[PDF][PDF] Basic and clinical aspects of fibrinolysis and thrombolysis
D Collen, HR Lijnen - 1991 - researchgate.net
LOOD CONTAINS an enzymatic system called the B fibrinolytic system, one of the main
functions of which is the dissolution of fibrin clots in the blood vessels. The fibrinolytic system …
functions of which is the dissolution of fibrin clots in the blood vessels. The fibrinolytic system …
Tissue-type plasminogen activator as a therapeutic target in stroke
I Gravanis, SE Tsirka - Expert opinion on therapeutic targets, 2008 - Taylor & Francis
Background: Ischemic stroke is a leading cause of morbidity and mortality worldwide and
recombinant human tissue-type plasminogen activator (tPA) is the prominent therapeutic …
recombinant human tissue-type plasminogen activator (tPA) is the prominent therapeutic …
[BOOK][B] Mammal teeth: origin, evolution, and diversity
PS Ungar - 2010 - books.google.com
Winner, 2010 PROSE Award for Excellence in the Biological Sciences. Professional and
Scholarly Publishing division of the Association of American Publishers In this unique book …
Scholarly Publishing division of the Association of American Publishers In this unique book …
The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate
The effectiveness of fibrinolysis results from the combination of regulated enzymatic activity
and the physical properties of the fibrin scaffold. Physiologically, clots or thrombi are …
and the physical properties of the fibrin scaffold. Physiologically, clots or thrombi are …
Thrombolytic agents: nanocarriers in controlled release
Thrombosis is a life‐threatening pathological condition in which blood clots form in blood
vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes …
vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes …
[HTML][HTML] Structural biology and protein engineering of thrombolytics
Myocardial infarction and ischemic stroke are the most frequent causes of death or disability
worldwide. Due to their ability to dissolve blood clots, the thrombolytics are frequently used …
worldwide. Due to their ability to dissolve blood clots, the thrombolytics are frequently used …
Tissue-type plasminogen activator: characteristics, applications and production technology
SA Rouf, M Moo-Young, Y Chisti - Biotechnology advances, 1996 - Elsevier
Plasminogen activators have immense clinical significance as thrombolytic agents for
management of stroke and myocardial infarction. Tissue-type plasminogen activator (tPA) is …
management of stroke and myocardial infarction. Tissue-type plasminogen activator (tPA) is …
Approaching the golden age of natural product pharmaceuticals from venom libraries: an overview of toxins and toxin-derivatives currently involved in therapeutic or …
Poisons and the toxins found in venomous and poisonous organisms have been the focus of
much research over the past 70 years, most of which has been directed at understanding the …
much research over the past 70 years, most of which has been directed at understanding the …
[HTML][HTML] High resolution analysis of functional determinants on human tissue-type plasminogen activator.
WF Bennett, NF Paoni, BA Keyt, D Botstein… - Journal of Biological …, 1991 - Elsevier
Sixty-four variants of human tissue-type plasminogen activator (tPA) were produced using
recombinant DNA techniques. Charged residues were converted to alanine in clusters of …
recombinant DNA techniques. Charged residues were converted to alanine in clusters of …
[HTML][HTML] Isolation, sequence analysis, and cloning of haemadin. An anticoagulant peptide from the Indian leech.
KH Strube, B Kröger, S Bialojan, M Otte… - Journal of Biological …, 1993 - Elsevier
A slow, tight-binding inhibitor of thrombin with an apparent molecular mass of about 5 kDa
has been isolated from Haemadipsa sylvestris, an Indian leech of the family of …
has been isolated from Haemadipsa sylvestris, an Indian leech of the family of …